A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis

References

• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–2627.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Leukemia. 2021.
   Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385(1):46–58.
   PubMed Web of Science ®Google Scholar
• Rare diseases: not so out of the ordinary. Lancet Haematol. 2020;7(3):e177.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–4390.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A european collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280.
   PubMed Web of Science ®Google Scholar
• Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014;28(12):2304–2310.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014;28(12):2311–2316.
   PubMed Web of Science ®Google Scholar
• Olimpieri PP, Di Lenarda A, Mammarella F, et al. Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: insights from italian monitoring registries. Int J Cardiol Heart Vasc. 2020;26:100465.
   PubMed Web of Science ®Google Scholar
• Breccia M, Olimpieri PP, Olimpieri O, et al. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer Med. 2020;9(12):4160–4165.
   PubMed Web of Science ®Google Scholar
• Breccia M, Celant S, Olimpieri PP, et al. Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). Ann Hematol. 2021;100(2):481–485.
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;125(14):2239–2244.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119(8):1844–1847.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Palladini G, Schonland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28(1):1–2.
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M, Kyle R, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
   PubMed Web of Science ®Google Scholar
• Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992;11(14–15):1871–1879.
   PubMed Web of Science ®Google Scholar
• Palladini G, Schonland S, Merlini G, et al. First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network. Blood. 2020;136(Supplement 1):50–51.
   PubMedGoogle Scholar
• Reece D, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489–1497.
   PubMed Web of Science ®Google Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–873.
   PubMed Web of Science ®Google Scholar